{"id":27482,"date":"2014-10-01T12:51:32","date_gmt":"2014-10-01T12:51:32","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=27482"},"modified":"2014-12-01T14:12:59","modified_gmt":"2014-12-01T14:12:59","slug":"27482","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/27482","title":{"rendered":"September\/October 2014: Volume 15 Number 9\/10"},"content":{"rendered":"<p><a href=\"https:\/\/i-base.info\/htb\/date\/2014\/10\">Full contents<\/a>.<\/p>\n<p><strong>This edition of HTB includes conference reports from the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and a few final ones from the 20th International AIDS Conference (IAS 2014).<\/strong><\/p>\n<p>Updates from <a href=\"https:\/\/i-base.info\/htb\/27480\">ICAAC<\/a> include: news on tenofovir alafenamide, suggesting potential bone and renal benefits with this compared to the current formulation of tenofovir; non-inferiority of cobicistat for boosting atazanavir compared to ritonavir; an update on the pipeline NNRTI doravirine; a post-hoc analysis of Stribild in black participants; and tenofovir gel for prevention.<\/p>\n<p>We are grateful to NATAP and include their ICAAC reports on switching from Atripla to Eviplera, which significantly reduced central nervous system toxicity; on the detection of HIV in lung alveolar macrophages; and low US uptake of HCV treatment in a 2008-2013 analysis of the VA cohort in Washington.<\/p>\n<p>Reports from <a href=\"https:\/\/i-base.info\/htb\/27470\">AIDS 2014<\/a> cover the PROUD study of oral PrEP &#8211; with discussion about access to Truvada for PrEP in the UK and Europe; high baseline rates of COPD in a substudy of the START trial; the risk of cardiovascular disease or type-2 diabetes according to change in BMI after starting ART; and loss to follow up in the Malawi Option B+ programme &#8211; which needs some improvement.<\/p>\n<p>Recent new ARV approvals are: the new <a href=\"https:\/\/i-base.info\/htb\/27457\">FDC of dolutegravir plus abacavir and 3TC<\/a>; <a href=\"https:\/\/i-base.info\/htb\/27453\">cobicistat and elvitegravir<\/a> as single agents in the US and a positive opinion for co-formulated <a href=\"https:\/\/i-base.info\/htb\/27415\">darunavir\/cobicistat<\/a> in Europe. For hepatitis C treatment, <a href=\"https:\/\/i-base.info\/htb\/27430\">daclatasvir was approved<\/a> in Europe for genotypes 1-4 and the CHMP gave a positive opinion to approve co-formulated <a href=\"https:\/\/i-base.info\/htb\/27428\">sofosbuvir\/ledipasvir<\/a>.<\/p>\n<p>Other antiretroviral news includes data on raltegravir in pregnancy and for infants; efavirenz PK in pregnancy and in the presence of rifampicin for TB treatment and a report showing kidney signal trouble worsens over 5 years in a Japanese cohort receiving tenofovir.<\/p>\n<p>Gareth Hardy reviews two important journal papers: one reporting little clinical impact from HIV reinfection (so long as drug resistance is not an issue) and a second reporting an experimental approach to treating PML that may be applicable for HIV positive people.<\/p>\n<p>And Richard Jefferys once again updates us on basic science and cure research.<\/p>\n<p><a href=\"https:\/\/i-base.info\/htb\/date\/2014\/10\">Full contents<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Reports from the 54th ICAAC and IAS 2014 conferences, newly approved drugs for HIV and hepatitis C, new UK guidelines for pregnancy and PEP, plus a potential new approach for PML&#8230;<\/p>\n","protected":false},"author":2,"featured_media":27504,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-27482","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-editorial"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/27482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=27482"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/27482\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media\/27504"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=27482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=27482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=27482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}